{"doi":"10.1053/j.jfas.2013.07.003","title":"Chronic Leg Ulceration Associated with Polycythemia Vera Responding to Ruxolitinib (Jakafi®)","abstract":null,"journal":"The Journal of Foot and Ankle Surgery","year":2013,"id":656477,"datarank":0.5289540786924243,"base_score":3.5263605246161616,"endowment":3.5263605246161616,"self_citation_contribution":0.5289540786924243,"citation_network_contribution":0.0,"self_endowment_contribution":0.5289540786924243,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":33,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1713680,"name":"Sean McNish","orcid":null,"position":1,"is_corresponding":false},{"id":429740,"name":"Nawar Shara","orcid":"0000-0002-9005-252X","position":2,"is_corresponding":false},{"id":1713681,"name":"Katherine J. Hubley","orcid":null,"position":3,"is_corresponding":false},{"id":264146,"name":"Bhaskar Kallakury","orcid":"0000-0002-1298-2983","position":4,"is_corresponding":false},{"id":1713682,"name":"David M. Dunning","orcid":null,"position":5,"is_corresponding":false},{"id":1687757,"name":"Christopher E. Attinger","orcid":null,"position":6,"is_corresponding":false},{"id":769504,"name":"John S. Steinberg","orcid":"0000-0001-8100-4780","position":7,"is_corresponding":false},{"id":445767,"name":"Victoria K. Shanmugam","orcid":"0000-0002-5882-4884","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Chronic Leg Ulceration Associated with Polycythemia Vera Responding to Ruxolitinib (Jakafi®)","abstract":"We present the case of a 63-year-old white male with bilateral chronic leg ulcers due to polycythemia vera and hydroxyurea therapy who demonstrated dramatic healing of his wounds in response to ruxolitinib (Jakafi(®), Novartis), a novel Janus kinase-1 and -2 inhibitor. This patient's wound had previously been refractory to multiple surgical interventions and immunosuppression. After the initiation of ruxolitinib, the patient underwent successful split-thickness skin grafting, with resultant healing of his wounds. He was stable without prednisone and other immunosuppressant therapy and had healed at 6 months. Ruxolitinib therapy could represent a novel option for patients who develop persistent inflammatory wounds in the setting of polycythemia vera and hydroxyurea therapy.","is_dataset_classified":null,"base_score":3.5263605246161616,"endowment":3.5263605246161616,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23953278","pmcid":"PMC3925681","openalex_id":"https://openalex.org/W2033459852","authors":[],"funders":[{"funder_name":"NINR NIH HHS","grant_id":"R01 NR013888","title":null},{"funder_name":"NCATS NIH HHS","grant_id":"UL1 TR000101","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"KL2 RR031974","title":null},{"funder_name":"NCRR NIH HHS","grant_id":"UL1 RR031975","title":null}],"total_grants":4,"fwci":1.1768,"citation_percentile":0.77569183,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2013,"count":1},{"year":2014,"count":2},{"year":2015,"count":2},{"year":2016,"count":3},{"year":2017,"count":4},{"year":2018,"count":3},{"year":2019,"count":1},{"year":2020,"count":1},{"year":2022,"count":1},{"year":2023,"count":4},{"year":2024,"count":4},{"year":2025,"count":1},{"year":2026,"count":4}],"oa_status":"green","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3925681","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3925681","host_type":"repository"},{"url":"https://api.elsevier.com/content/article/PII:S1067251613003025?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1067251613003025?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1053/j.jfas.2013.07.003","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/23953278","host_type":"repository"}],"fields_of_study":["Myeloproliferative Neoplasms: Diagnosis and Treatment","Eosinophilic Disorders and Syndromes","Chronic Myeloid Leukemia Treatments"],"mesh_terms":["Antimetabolites","Chronic Disease","Enzyme Inhibitors","Humans","Hydroxyurea","Leg","Male","Middle Aged","Nitriles","Polycythemia Vera","Pyrazoles","Pyrimidines","Skin Ulcer","Wound Healing","Wounds and Injuries","Skin Transplantation","Janus Kinases"],"keywords":["Ruxolitinib","Polycythemia vera","Medicine","Polycythemia rubra vera","Myelofibrosis","Internal medicine","Dermatology","Hydroxyurea","Leg Ulcer","Pyoderma Gangrenosum","Chronic Wound","4","Split-thickness Skin Graft"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-11T21:02:55.763572Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}